This clinical trial is focused on studying unprovoked venous thromboembolism (VTE), which includes conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE). These are blood clots that occur without an obvious reason. The study is also interested in detecting hidden or “occult” cancer in patients who have experienced their first unprovoked VTE. The trial will use a special imaging technique called 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) to help find any hidden cancers. This imaging method combines two types of scans to provide detailed pictures of the inside of the body.

The purpose of the study is to see if using FDG PET/CT can find more hidden cancers compared to a more limited cancer screening approach. Patients who are 50 years or older and have recently been diagnosed with their first unprovoked VTE will be part of this study. The study will last for one year, during which participants will undergo the FDG PET/CT scan and follow-up checks to monitor for any signs of cancer. The study will also compare the results of this new screening method with traditional methods to see which is more effective in detecting cancer early.

Participants will receive an injection of a special substance called Gallium (68Ga) Chloride, which helps highlight areas of interest in the body during the scan. This substance is part of a product known as GalliaPharm. Some participants may receive a placebo instead. The study aims to improve cancer detection in patients with unprovoked VTE and to understand the potential benefits and costs of using advanced imaging techniques like FDG PET/CT in routine cancer screening. The findings from this study may help develop better screening strategies for future patients.